跳至主要内容
临床试验/KCT0001354
KCT0001354尚未招募未知

The Effect of Co-administration of Herbal extracts to Sorafenib (NexavarTM) on the QoL in patients with Hepatocellular carcinoma - pilot study

Comprehensive and Integrative Medical Institute0 个研究点目标入组 16 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 79(Year)(—)
性别
All

入选标准

  • 1.HCC patient who is taking Sorafenib or is planning to take Sorafenib.
  • 2.ECOG performance 0~2
  • 3.Age: 20 years ~ 80 years
  • 4.No disability of cognitive function
  • 5.Who voluntarily decide the participation of the study and sign the consent.
  • 6.The patients who can be possible to follow up during the study periods.

排除标准

  • 1.HCC patient who is planning to surgery or other chemotherapy.
  • 2.HCC patient who in needed surgical operation due to GI obstruction.
  • 3.Hypertension whitch is not controlled antihypertensive drug.
  • 4.Serum AST and ALT: above 150 U/mL, serum cratinine: above 3.4 mg/dL
  • 5.Who can not sign the consent.
  • 6.The patients who is inappropriated this study confirmed by researchers.
  • 7.Women who have posive urine hCG.

研究者

发起方
Comprehensive and Integrative Medical Institute

相似试验